story of the week
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs T-DM1 in ERBB2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
JAMA Oncol 2021 Jun 24;[EPub Ahead of Print], T Hatschek, T Foukakis, J Bjöhle, T Lekberg, H Fredholm, E Elinder, A Bosch, G Pekar, H Lindman, A Schiza, Z Einbeigi, J Adra, A Andersson, L Carlsson, AC Dreifaldt, E Isaksson-Friman, S Agartz, E Azavedo, P Grybäck, M Hellström, H Johansson, C Maes, I Zerdes, J Hartman, Y Brandberg, J BerghFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.